ZimVie (NASDAQ:ZIMV – Get Rating) issued an update on its FY 2022 earnings guidance on Thursday morning. The company provided EPS guidance of $2.100-$2.300 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.150. The company issued revenue guidance of $1 billion-$1 billion, compared to the consensus revenue estimate of $988.10 million.
A number of analysts have weighed in on the stock. Credit Suisse Group assumed coverage on shares of ZimVie in a report on Tuesday, March 1st. They issued an underperform rating and a $34.00 price target for the company. Guggenheim assumed coverage on ZimVie in a research report on Friday, March 18th. They set a neutral rating on the stock.
Shares of ZIMV stock opened at $27.32 on Thursday. ZimVie has a one year low of $21.52 and a one year high of $50.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.57 and a current ratio of 2.91.
ZimVie Inc involved in the Dental and Spine markets which develops, manufactures and delivers a portfolio of products and solutions designed to treat Spine pathologies and support Dental tooth replacement and restoration procedures. ZimVie Inc is headquartered in Westminster, Colorado.
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Greenbrier Companies Stock has Green in its Future
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.